
Artivion, Inc.
AORTNYSEHealthcareMedical - Devices
一般交易時段
US$26.84
−US$1.24 · -4.42%
AORT公司概覽
盤中時間採用ET。市場資料可能有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Hold
Wait — insufficient conviction to act
估值
60
Fair Value
動能
26
Weakening
情緒
72
Bullish
風險韌性
36
High Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
- 產業
- Medical - Devices
- 部門
- Healthcare
- 總部
- US
- 執行長
- James Patrick Mackin
- 上市以來
- 1993年2月12日
- 僱員
- 1,800
市場位置
日內區間
目前US$26.84,
52週區間
目前US$26.84,
- 開盤價
- US$28.01
- 前收盤價
- US$28.08
- 成交量
- 24.57萬
- 0.33× 平均值
- 平均成交量
- 73.45萬
- 日均成交量
- 市值
- 13.03億 USD
- 貝塔
- 1.25
- 市場參考 1
- 50天平均值
- US$24.9674
- 高於平均水平+7.50%
- 200天平均值
- US$34.7026
- 低於平均水平-22.66%
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 22.95億 USD
- 本益比(TTM)
- -450.34×
- 股價淨值比(TTM)
- 2.92×
- 股價營收比(TTM)
- 2.76×
- EV/EBITDA
- 35.96×
- 盈餘收益率
- 0.47%
- 自由現金流收益率
- -0.04%
- 股息率
- 0.00%
獲利能力和效率
- 毛利率
- 62.80%
- 營業利益率
- 4.00%
- 淨利潤率
- -0.67%
- 股東權益報酬率
- 2.18%
- 資產報酬率
- 1.10%
- 投入資本報酬率
- 2.24%
財務健康
- 負債權益比
- 0.92×
- 流動比率
- 2.99×
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4.41億 USD | 3.89億 USD | 3.54億 USD | 3.14億 USD | 2.99億 USD |
| 銷貨成本 | 1.71億 USD | 1.4億 USD | 1.25億 USD | 1.11億 USD | 1.01億 USD |
| 毛利 | 2.7億 USD | 2.49億 USD | 2.29億 USD | 2.03億 USD | 1.98億 USD |
| 研究與開發 | 3099.1萬 USD | 2845.2萬 USD | 2870.7萬 USD | 3887.9萬 USD | 3554.6萬 USD |
| 銷售、一般及管理費用 | 2.13億 USD | 1.92億 USD | 2.09億 USD | 1.57億 USD | 1.7億 USD |
| 營業費用 | 2.44億 USD | 2.1億 USD | 2.23億 USD | 1.96億 USD | 1.89億 USD |
| 利息收入 | 76.3萬 USD | 146.7萬 USD | 107.7萬 USD | 14.7萬 USD | 7.9萬 USD |
| 利息支出 | 2658.2萬 USD | 3427.7萬 USD | 2529.9萬 USD | 1822.4萬 USD | 1688.7萬 USD |
| 折舊和攤銷 | 2245.8萬 USD | 2420.5萬 USD | 2307.6萬 USD | 2244.2萬 USD | 2397.7萬 USD |
| 營業利益 | 2674.5萬 USD | 3887.4萬 USD | 574.2萬 USD | 620.1萬 USD | 811.7萬 USD |
| 淨利 | 976.8萬 USD | −1335.9萬 USD | −3069萬 USD | −1919.2萬 USD | −1483.4萬 USD |
公司資料更新於 2026年8月24日。
AORT同業公司
持有AORT的ETF
報告持有此股票曝險的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR7365.05萬0.07%1111.89億 USD0.06%US$146.55-0.52%
Vanguard Morningstar Total Stock Market ETFVTI3926.14萬0.00%2.3兆 USD0.03%US$377.16-0.29%
iShares Russell 2000 ETFIWM3262.18萬0.04%816.21億 USD0.19%US$297.82-0.71%
Vanguard Extended Market ETFVXF1319.49萬0.01%937億 USD0.05%US$243.29-0.91%
iShares Russell 2000 Growth ETFIWO1204.33萬0.08%151.65億 USD0.24%US$383.01-1.13%
iShares S&P Small-Cap 600 Growth ETFIJT1116.07萬0.13%82.16億 USD0.18%US$173.03-0.50%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM1111.37萬0.07%170.31億 USD0.03%US$56.995-0.50%
Invesco S&P SmallCap Momentum ETFXSMO696.29萬0.23%30.36億 USD0.36%US$85.145-1.05%
iShares Core S&P Small-Cap ETFIJR- 市場價值
- 7365.05萬
- 重量
- 0.07%
- AUM
- 1111.89億 USD
- 費用率
- 0.06%
- 價格 / 1日
- US$146.55-0.52%
Vanguard Morningstar Total Stock Market ETFVTI- 市場價值
- 3926.14萬
- 重量
- 0.00%
- AUM
- 2.3兆 USD
- 費用率
- 0.03%
- 價格 / 1日
- US$377.16-0.29%
iShares Russell 2000 ETFIWM- 市場價值
- 3262.18萬
- 重量
- 0.04%
- AUM
- 816.21億 USD
- 費用率
- 0.19%
- 價格 / 1日
- US$297.82-0.71%
Vanguard Extended Market ETFVXF- 市場價值
- 1319.49萬
- 重量
- 0.01%
- AUM
- 937億 USD
- 費用率
- 0.05%
- 價格 / 1日
- US$243.29-0.91%
iShares Russell 2000 Growth ETFIWO- 市場價值
- 1204.33萬
- 重量
- 0.08%
- AUM
- 151.65億 USD
- 費用率
- 0.24%
- 價格 / 1日
- US$383.01-1.13%
iShares S&P Small-Cap 600 Growth ETFIJT- 市場價值
- 1116.07萬
- 重量
- 0.13%
- AUM
- 82.16億 USD
- 費用率
- 0.18%
- 價格 / 1日
- US$173.03-0.50%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM- 市場價值
- 1111.37萬
- 重量
- 0.07%
- AUM
- 170.31億 USD
- 費用率
- 0.03%
- 價格 / 1日
- US$56.995-0.50%
Invesco S&P SmallCap Momentum ETFXSMO- 市場價值
- 696.29萬
- 重量
- 0.23%
- AUM
- 30.36億 USD
- 費用率
- 0.36%
- 價格 / 1日
- US$85.145-1.05%
繼續GoAI的研究
在 GoAI 中研究AORTresearch.disclaimer





